General Information of DTT (ID: TTKN7QR)

DTT Name BDNF/NT-3 growth factors receptor (TrkB) DTT Info
UniProt ID
NTRK2_HUMAN
Gene Name NTRK2

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Patented Agent(s)
Clinical Trial Drug(s)
2 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small cell lung cancer 2C25 Approved [1]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [2]
------------------------------------------------------------------------------------
1 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [3]
------------------------------------------------------------------------------------
11 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ Chronic pain MG30 Patented [4]
Azaindazole amide derivative 1 DMJWH4B Chronic pain MG30 Patented [4]
Cyclopenta[d]pyrimidine derivative 1 DMKM6BY N. A. N. A. Patented [5]
Macrocycle derivative 13 DM1KBSV Cell proliferative disorder FB86 Patented [5]
PMID28270010-Compound-Figure24-b DM0QHLK N. A. N. A. Patented [5]
PMID28270010-Compound-Figure5-1 DM2YAPJ N. A. N. A. Patented [5]
PMID28270010-Compound-Figure5-2 DMK3GRZ N. A. N. A. Patented [5]
PMID28270010-Compound-Figure5-3 DMSOT1R N. A. N. A. Patented [5]
PMID28270021-Compound-WO2015042088Example4 DM6KXOQ Chronic pain MG30 Patented [4]
PMID28270021-Compound-WO2016054807Example1 DMD5QEL Chronic pain MG30 Patented [4]
Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR Chronic pain MG30 Patented [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Patented Agent(s)
4 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
AZD1332 DM0PVD9 Discovery agent N.A. Investigative [6]
GNF-5837 DMYJO13 Discovery agent N.A. Investigative [7]
PMID24432909C8e DMEGAZS Discovery agent N.A. Investigative [8]
TrkB NAM DMBZI5F Neurodegenerative disorder 8A20-8A23 Investigative [6]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
4 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
5 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1818).
7 Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Med Chem Lett. 2012 Jan 1;3(2):140-5.
8 Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87.